Last reviewed · How we verify
Replacement with Zonisamide
Zonisamide is an anticonvulsant that blocks sodium and calcium channels in neurons, reducing abnormal electrical activity in the brain.
Zonisamide is an anticonvulsant that blocks sodium and calcium channels in neurons, reducing abnormal electrical activity in the brain. Used for Partial seizures (adjunctive therapy), Generalized tonic-clonic seizures (adjunctive therapy), Lennox-Gastaut syndrome (adjunctive therapy).
At a glance
| Generic name | Replacement with Zonisamide |
|---|---|
| Sponsor | Eisai Inc. |
| Drug class | Anticonvulsant / Antiepileptic drug |
| Target | Voltage-gated sodium channels, T-type calcium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Zonisamide inhibits voltage-gated sodium channels and T-type calcium channels, stabilizing neuronal membranes and reducing repetitive neuronal firing. It also has weak carbonic anhydrase inhibitory activity. These combined effects suppress seizure propagation and reduce the frequency of seizure episodes.
Approved indications
- Partial seizures (adjunctive therapy)
- Generalized tonic-clonic seizures (adjunctive therapy)
- Lennox-Gastaut syndrome (adjunctive therapy)
Common side effects
- Somnolence
- Ataxia
- Dizziness
- Anorexia
- Headache
- Nausea
- Cognitive dysfunction
- Nephrolithiasis
- Hypohidrosis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Replacement with Zonisamide CI brief — competitive landscape report
- Replacement with Zonisamide updates RSS · CI watch RSS
- Eisai Inc. portfolio CI